Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Sipagladenant
Sipagladenant (KW-6356) is a non-xanthine selective antagonist/inverse agonist of the adenosine A2A receptor that was previously under development by Kyowa Kirin as a monotherapy and adjunctive to levodopa therapy in Parkinsonism.
KW-6356 is a selective A2A adenosine antagonist/inverse agonist displaying insurmountable antagonism of this adenosine subtype. Compared to the first generation A2A adenosine inverse agonist Istradefylline, KW-6356 possesses a 100-fold greater affinity for the A2A adenosine receptor and dissociates more slowly from the receptor.
The metabolism of KW-6356 generates M6, an active metabolite with similar potency as a A2A antagonist/inverse agonist.
The half-life of KW-6356 is 22.9 hours. The half-life of M6 is 4.34 hours.
Kyowa Kirin halted development of KW-6356 in 2022 based on regulatory and developmental challenges surrounding the drug.
Hub AI
Sipagladenant AI simulator
(@Sipagladenant_simulator)
Sipagladenant
Sipagladenant (KW-6356) is a non-xanthine selective antagonist/inverse agonist of the adenosine A2A receptor that was previously under development by Kyowa Kirin as a monotherapy and adjunctive to levodopa therapy in Parkinsonism.
KW-6356 is a selective A2A adenosine antagonist/inverse agonist displaying insurmountable antagonism of this adenosine subtype. Compared to the first generation A2A adenosine inverse agonist Istradefylline, KW-6356 possesses a 100-fold greater affinity for the A2A adenosine receptor and dissociates more slowly from the receptor.
The metabolism of KW-6356 generates M6, an active metabolite with similar potency as a A2A antagonist/inverse agonist.
The half-life of KW-6356 is 22.9 hours. The half-life of M6 is 4.34 hours.
Kyowa Kirin halted development of KW-6356 in 2022 based on regulatory and developmental challenges surrounding the drug.